.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

UROXATRAL Drug Profile

« Back to Dashboard
Uroxatral is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in thirty-eight countries.

The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.

Summary for Tradename: UROXATRAL

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Drug Prices: :see details

Pharmacology for Tradename: UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
UROXATRAL
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 2003RXYes6,149,940*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc
UROXATRAL
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 20034,661,491*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: UROXATRAL

Drugname Dosage Strength RLD Submissiondate
alfuzosin hydrochlorideExtended-release Tablets10 mgUroxatral6/12/2007

International Patent Family for Tradename: UROXATRAL

Country Document Number Estimated Expiration
Cyprus2284► subscribe
Germany69704712► subscribe
Argentina009312► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc